Last updated: 11/07/2018 16:04:20
Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A multi-centre, randomised, double-blind, double dummy study comparing the efficacy and safety of chlorproguanil-dapsone-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in children and adolescents in Africa.
Trial description: Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK’s Medicines and Healthcare products Regulatory Agency.CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a treatment for acute uncomplicated P. falciparum malaria. The combination of chlorproguanil-dapsone-artesunate (CDA) is being developed to supersede chlorproguanil-dapsone for the same indication, but the addition of an artemisinin derivative, artesunate, should provide additional population benefits over chlorproguanil-dapsone alone. The artemisinins have been demonstrated to rapidly reduce parasite load and have activity against the sexual stages of the P.falciparum lifecycle. The addition of a second agent to the chlorproguanil-dapsone combination should also protect against the selection of resistant strains of P.falciparum. Artemether-lumefantrine is the only available fixed-dose Artemisinin-based Combination Therapy actually available and is considered as the gold standard for the treatment of P. falciparum malaria. This study will therefore aim to demonstrate the non-inferiority of the combination of CDA to artemether-lumefantrine in terms of efficacy at 28-days. The key secondary objectives will compare the Parasite Clearance Times (PCT) and the Fever Clearance Times (FCT) between CDA and artemether-lumefantrine.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Parasitological cure rate, PCR corrected, at day 28 in the PP population The ITT population is a key supportive analysis.
Timeframe: N/A
Secondary outcomes:
Parasitological cure rate, PCR-corrected, at day 14 and 42 ACPR, and ACPR PCR corrected at day 14, 28 and 42 Summary of asexual parasite densities on days 0, 1, 2, 3, 7, 14, 28 and 42 by treatment group.
Timeframe: N/A
Interventions:
Drug: chlorproguanil-dapsone-artesunate
Drug: artemether-lumefantrine
Enrollment:
1395
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Lucio Luzzatto, Naomi Richardson, Nick Carter, Stephan Duparc, Zul Premji, Alfred Tiono, Allan Pamba. Clinical spectrum of hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120:4123-4133.
Medical condition
Malaria, Falciparum
Product
artesunate, artesunate/chlorproguanil/dapsone, chlorproguanil, dapsone
Collaborators
Not applicable
Study date(s)
June 2006 to August 2007
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
12 months - 14 years
Accepts healthy volunteers
No
- Acute, uncomplicated P.falciparum malaria, microscopically confirmed
- Temperature at screening of 37.5oC or or more or confirmed history of fever within previous 24 hours
- Features of severe/complicated falciparum malaria
- Hypersensitivity to active substances (chlorproguanil, dapsone, artesunate, artemether, lumefantrine)
Inclusion and exclusion criteria
Inclusion criteria:
- Acute, uncomplicated P.falciparum malaria, microscopically confirmed
- Temperature at screening of 37.5oC or or more or confirmed history of fever within previous 24 hours
- Weigh 7.5kg or over
- Screening haemoglobin (Hb) of 7g/dl or over, or haematocrit of 25% or more(If Hb not available at screening)
- Willingness to comply with the study visits and procedures, as outlined in the informed consent form
- Written or oral witnessed consent has been obtained from parent or guardian
- Assent is given by a child aged 12 years or over, in addition to the consent of their parent or guardian
Exclusion criteria:
- Features of severe/complicated falciparum malaria
- Hypersensitivity to active substances (chlorproguanil, dapsone, artesunate, artemether, lumefantrine)
- Known allergy to biguanides, sulphones, sulphonamides, artemisinin derived products or aminoalcohol drugs
- Known history of G6PD deficiency
- Infants with a history of hyperbilirubinaemia during the neonatal period
- Use of concomitant medications that may induce haemolysis or haemolytic anaemia from the WHO (World Health Organization) list of essential drugs
- Evidence of any concomitant infection at the time of presentation (including P. vivax, P. ovale and P. malariae)
- Any other underlying disease that may compromise the diagnosis and the evaluation of the response to the study medication (including clinical symptoms of immunosuppression, tuberculosis, bacterial infection; cardiac or pulmonary disease)
- Malnutrition, defined as a child whose weight-for-height is below -3 standard deviations or less than 70% of the median of the NCHS/WHO normalised reference values
- Treatment within the past three months with mefloquine or mefloquine-sulphadoxine-pyrimethamine; twenty-eight days with sulphadoxine/pyrimethamine, sulfalene/pyrimethamine, lumefantrine or artemether/lumefantrine, amodiaquine, atovaquone or atovoquone/proguanil, halofantrine; 14-days with chlorproguanil/dapsone, or 7-days with quinine (full course), proguanil, artemisinins, tetracycline doxycycline or clindamycin
- Positive sulphadoxine/pyrimethamine urine screen for 'unknown' antimalarial drug use in prior 28-days
- Use of an investigational drug within 30 days or 5 half-lives whichever is the longer
- Previous participation in this study
- Female subjects of child-bearing age, who have had a positive pregnancy test at screening, or do not give their consent to take a pregnancy test
- Female subjects who will be breast-feeding an infant for the duration of the study
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2007-04-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website